Ananta Addala
725 WELCH RD · Palo Alto, CA 94304
Stanford Health Care Bariatric Surgery and Medical Weight Loss · Palo Alto, CA 94304
2.7· 7 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Stanford Health Care Bariatric Surgery and Medical Weight Loss is a Stanford Health Care program in Palo Alto, California, and its listing shows weight-loss care and endocrine services. On Google it holds a 2.7-star rating across 7 reviews dating back to 2017, none in the past year. Reviewers mention results most often, in 3 reviews, and two reviews each mention billing and scheduling.
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Counts computed by RetaMaps from public Google reviews; most recent review 2023-11-07. Read the reviews themselves on the practice's Google listing.
Rated ★2.7 across 7 Google reviews. Of the 7 reviews we analyzed, 3 (43%) are positive (4–5★) and 4 (57%) are negative (1–2★).
Not enough detailed reviews to summarize.
Forrest C.★★★★★2023-11-07Hours say open until 5pm Arrived at 4:30pm Clinic next door said they have been closed since 2pm Extremely frustrating
Mah K.★★★★★2023-10-14This clinic is absolutely amazing and the staff is incredible!
T F.★★★★★2022-06-16The clinic only provides virtual appointments for the medical weight loss program. I started the medical weight loss program in 2018, and it was wonderful; then, the pandemic began in 2020. I gained weight the same year from being sedentary, and the office stopped seeing patients in person. Since 2020 keeping weight off has been difficult. I need one-on-one help, and Stanford provided that for me when I started my weight loss journey. At the beginning of the pandemic, I understand closing the office. However, it’s 2022, and in a few months will be 2023. It’s time to open the clinic with COVID precautions like every other place in the Bay Area. COVID isn’t going anywhere, and I’m surprised that an elite university hospital like Stanford can’t figure out how to navigate in-person appointments. Every doctor's and dentist's office I visit sees patients face to face with no issue. Virtual appointments are a disservice to patients that struggle with weight issues and need in person support.
Debbie B.★★★★★2022-03-30Ridiculously expensive, first consultation itself was a$1000! If I spent $1000 on a nutritionist I’d do better
Christina T.★★★★★2021-05-24I received my Gastric bypass in the summer of 2010, my Dr & surgeon was Dr. Homero Rivas. He was a very kind doctor and always made me feel positive about myself. I would really recommend him if you’re interested in getting any type of Gastric surgery for weight loss when the weight is effecting or causing other medical problems.
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
725 WELCH RD · Palo Alto, CA 94304
300 PASTEUR DR · Palo Alto, CA 94304
3801 MIRANDA AVE, MAIL CODE 111/ENDO · Palo Alto, CA 94304
540 Bryant Street · Palo Alto, CA 94301
4.8(16 Google reviews · 4 in past year)
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs